{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:11:41Z","timestamp":1785427901272,"version":"3.56.0"},"reference-count":19,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cancer Care Ontario (Ministry of Health, Ontario)"},{"name":"Faculty of Medicine, University of Ottawa"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The reasons why patients cannot proceed with HCT, including cases where no suitable donor is identified, remain poorly described. We reviewed all referrals for allogeneic HCT to our programme between 1 January 2019 and 31 December 2023. Of 880 patients referred for allogeneic HCT, 494 (61.8%) proceeded to transplant (mean 52 \u00b1 14.8 years, 61.5% male) using HLA-matched unrelated (64.2%) or related (19.4%) donors and HLA-mismatched (13%) or haploidentical (3%) donors. Of patients that did not proceed with HCT (386, 38.2%), disease-related causes (54.2%), patient preference (15.8%), and significant patient comorbidity (11.4%) were the most common reasons. Eleven patients (2.9% of transplants that did not proceed; 1.3% of all referrals) lacked a suitable donor and had HLA phenotypes most associated with Caucasian (six patients, 55%), First Nations, Inuit or Metis (two patients, 18%), Black African, Caribbean or African American (one patient, 9%), Asian or Pacific Islander (9%), or unknown ethnicity (one patient, 9%). Very few patients were unable to proceed with transplant due to lack of a suitable donor; however, those cases are overrepresented by non-Caucasian ethnicity relative to the population.<\/jats:p>","DOI":"10.3390\/curroncol32090483","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T16:42:21Z","timestamp":1756485741000},"page":"483","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Selection of Patients for Allogeneic HCT at a Single Centre: Lack of a Suitable Donor and Other Reasons for Not Proceeding"],"prefix":"10.3390","volume":"32","author":[{"given":"Madeline","family":"Monaghan","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Duong","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalina","family":"Abrol","sequence":"additional","affiliation":[{"name":"Transplantation & Cellular Therapy Program, Department of Medicine (Hematology), The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang","family":"Doan","sequence":"additional","affiliation":[{"name":"Transplantation & Cellular Therapy Program, Department of Medicine (Hematology), The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Cieniak","sequence":"additional","affiliation":[{"name":"Transplantation & Cellular Therapy Program, Department of Medicine (Hematology), The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6168-3939","authenticated-orcid":false,"given":"Harold","family":"Atkins","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada"},{"name":"Transplantation & Cellular Therapy Program, Department of Medicine (Hematology), The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Kekre","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada"},{"name":"Transplantation & Cellular Therapy Program, Department of Medicine (Hematology), The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Masurekar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada"},{"name":"Transplantation & Cellular Therapy Program, Department of Medicine (Hematology), The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Vasudevan Nampoothiri","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada"},{"name":"Transplantation & Cellular Therapy Program, Department of Medicine (Hematology), The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosh","family":"Thyagu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada"},{"name":"Transplantation & Cellular Therapy Program, Department of Medicine (Hematology), The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher N.","family":"Bredeson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada"},{"name":"Transplantation & Cellular Therapy Program, Department of Medicine (Hematology), The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5920-2736","authenticated-orcid":false,"given":"Michael","family":"Kennah","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada"},{"name":"Transplantation & Cellular Therapy Program, Department of Medicine (Hematology), The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-8289","authenticated-orcid":false,"given":"David S.","family":"Allan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada"},{"name":"Transplantation & Cellular Therapy Program, Department of Medicine (Hematology), The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.6004\/jnccn.2020.0021","article-title":"Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Saad","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1182\/blood-2011-11-354563","article-title":"Selection of optimal alternative graft source: Mismatched unrelated donor, umbilical cord blood, or haploidentical transplant","volume":"119","author":"Ballen","year":"2012","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2014-02-514760","article-title":"Hematopoietic stem cell transplantation donor sources in the 21st century: Choosing the ideal donor when a perfect match does not exist","volume":"124","author":"Kekre","year":"2014","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"346.e1","DOI":"10.1016\/j.jtct.2023.03.007","article-title":"Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research","volume":"29","author":"Auletta","year":"2023","journal-title":"Transpl. Cell Ther."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Nunes, K., Aguiar, V.R.C., Silva, M., Sena, A.C., de Oliveira, D.C.M., Dinardo, C.L., Kehdy, F.S.G., Tarazona-Santos, E., Rocha, V.G., and Carneiro-Proietti, A.B.F. (2020). How Ancestry Influences the Chances of Finding Unrelated Donors: An Investigation in Admixed Brazilians. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.584950"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"686.e1","DOI":"10.1016\/j.jtct.2023.08.014","article-title":"Existence of HLA-Mismatched Unrelated Donors Closes the Gap in Donor Availability Regardless of Recipient Ancestry","volume":"29","author":"Chowdhury","year":"2023","journal-title":"Transpl. Cell Ther."},{"key":"ref_10","unstructured":"(2025, June 09). Visible Minority and Population Group by Generation Status: Canada, Provinces and Territories, Census Metropolitan Areas and Census Agglomerations with Parts. (statcan.gc.ca). Available online: https:\/\/www12.statcan.gc.ca\/census-recensement\/2021\/as-sa\/fogs-spg\/page.cfm?dguid=2021A000011124&lang=E&topic=10."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/trf.17310","article-title":"Modelling unrelated blood stem cell donor recruitment using simulated registrant cohorts: Assessment of human leukocyte antigen matching across ethnicity groups","volume":"63","author":"Blake","year":"2023","journal-title":"Transfusion"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1182\/bloodadvances.2018028662","article-title":"Racial disparities in access to HLA-matched unrelated donor transplants: A prospective 1312-patient analysis","volume":"3","author":"Barker","year":"2019","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/trf.15795","article-title":"Improving access to better HLA-matched unrelated donors for hematopoietic cell transplantation for Canadian patients: Analysis of donor workups and selections in 2018","volume":"60","author":"Elmoazzen","year":"2020","journal-title":"Transfusion"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/hematology.2021000259","article-title":"Increasing access to allotransplants in the United States: The impact of race, geography, and socioeconomics","volume":"2021","author":"Hong","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101480","DOI":"10.1016\/j.beha.2023.101480","article-title":"Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program","volume":"36","author":"Yusuf","year":"2023","journal-title":"Best Pr. Res. Clin. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1182\/bloodadvances.2023009765","article-title":"Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors","volume":"7","author":"Bashey","year":"2023","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/vox.13619","article-title":"Determining the impact of current Canadian stem cell registry policy on donor availability via dynamic registry simulation","volume":"119","author":"Blake","year":"2024","journal-title":"Vox Sang."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/s41409-025-02571-9","article-title":"Frailty assessment and outpatient pre-habilitation for adults undergoing allogeneic hematopoietic cell transplantation","volume":"60","author":"Salas","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.bbmt.2020.07.020","article-title":"FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed\/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"26","author":"Labopin","year":"2020","journal-title":"Biol. Blood Marrow Transplant."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/9\/483\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:35:22Z","timestamp":1760034922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/9\/483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["curroncol32090483"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32090483","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]}}}